ProPhase Labs, Inc. Shares Issued, Shares, Share-based Payment Arrangement, Forfeited
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ProPhase Labs, Inc. shares issued, shares, share-based payment arrangement, forfeited for the quarter ending 2019-06-30 was 50.00 shares.
- ProPhase Labs, Inc. shares issued, shares, share-based payment arrangement, forfeited for the quarter ending 2019-03-31 was 30.00 shares.
| Period end | Shares Issued, Shares, Share-based Payment Arrangement, Forfeited 3 month | Shares Issued, Shares, Share-based Payment Arrangement, Forfeited 12 month |
|---|---|---|
| 2019-06-30 | 50.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | |
| 2019-03-31 | 30.00 shares 10-Q · filed 2019-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |